Genentech

A→Z catalog of Genentech

A

• Actemra / RoActemra — Tocilizumab — RA, JIA, GCA, cytokine release syndrome, COVID-19 — 4–8 mg/kg IV q4w or 162 mg SC q1–2w.

• Alecensa — Alectinib — ALK+ NSCLC — 600 mg BID.

• Avastin — Bevacizumab — Solid tumors (CRC, NSCLC, RCC, GBM, cervical, ovarian) — 5–15 mg/kg IV q2–3w.

• Actimmune (legacy rights US) — Interferon gamma-1b — Chronic granulomatous disease, osteopetrosis.

• Activase — Alteplase — Acute ischemic stroke, MI, PE — IV weight-based infusion.

B

• Boniva — Ibandronate — Osteoporosis — 150 mg PO monthly or 3 mg IV q3m.

• **Botox (US co-rights historically with Allergan)*.

• Brukinsa (co-market some regions) — Zanubrutinib.

C

• CellCept — Mycophenolate mofetil — Organ transplant immunosuppression — 1–1.5 g BID.

• Cathflo Activase — Alteplase — Catheter clearance — 2 mg instilled.

• Cotellic — Cobimetinib — BRAF V600 melanoma (with vemurafenib) — 60 mg daily (21/28 days).

• Columvi — Glofitamab — R/R DLBCL — IV step-up dosing + obinutuzumab pre-treatment.

D

• Dalcetrapib (terminated dev, not marketed).

• Diaport system (regional insulin pump).

E

• Erivedge — Vismodegib — Advanced basal cell carcinoma — 150 mg daily.

• Esbriet — Pirfenidone — Idiopathic pulmonary fibrosis — 801 mg TID.

• Evrysdi — Risdiplam — Spinal muscular atrophy — 5 mg PO daily (≥2 yrs).

F

• Fuzeon — Enfuvirtide — HIV (fusion inhibitor) — 90 mg SC BID.

• **Forane (legacy anesthetic, regional rights)*.

G

• Gazyva / Gazyvaro — Obinutuzumab — CLL, FL — IV infusion cycle-based.

• Granulocyte-CSF (Filgrastim, Pegfilgrastim biosimilars co-developed).

H

• Hemlibra — Emicizumab — Hemophilia A prophylaxis — 3 mg/kg SC weekly ×4, then 1.5 mg/kg weekly (or alt regimens).

• Herceptin — Trastuzumab — HER2+ breast/gastric cancer — IV or SC q1–3w (loading then maintenance).

• Herceptin Hylecta / SC — Subcutaneous trastuzumab.

• Herceptin Biosimilars (Ogivri, Kanjinti — not Genentech origin, but competition).

I

• Invirase — Saquinavir — HIV (older protease inhibitor).

• Inlyta (regional Pfizer drug, not Genentech).

J

• Jevtana (cabazitaxel distribution in some markets).

K

• Kadcyla — Trastuzumab emtansine (T-DM1) — HER2+ breast cancer — 3.6 mg/kg IV q3w.

• Kanuma (alfa sebelipase, co-market some regions).

L

• Lucentis — Ranibizumab — Wet AMD, DME, RVO, myopic CNV — 0.5 mg intravitreal injection monthly or PRN.

• Lunsumio — Mosunetuzumab — R/R FL — IV step-up dosing schedule.

• Lunsumio SC (in trials, EU approval).

M

• MabThera / Rituxan — Rituximab — NHL, CLL, RA, GPA, MPA, pemphigus vulgaris — 375 mg/m² IV weekly ×4 (oncology regimens).

• Mosunetuzumab (Lunsumio) — see L.

• Mircera (co-market, Roche nephrology).

N

• Nutropin AQ — Somatropin — Growth hormone deficiency — SC daily individualized.

• Neutropin (regional GH).

• Nutropin Depot (legacy).

O

• Ocrevus — Ocrelizumab — Relapsing MS, primary progressive MS — 600 mg IV q6m (split-dose initiation).

• Odomzo — Sonidegib — Basal cell carcinoma — 200 mg daily.

• Orencia (not Genentech, BMS drug).

P

• Polivy — Polatuzumab vedotin — DLBCL (with bendamustine + rituximab) — 1.8 mg/kg IV q3w.

• Perjeta — Pertuzumab — HER2+ breast cancer (with trastuzumab + chemo) — 840 mg IV load → 420 mg IV q3w.

• Pulmozyme — Dornase alfa — Cystic fibrosis — 2.5 mg inhaled daily.

• Pegasys — Peginterferon alfa-2a — Chronic HBV/HCV — 180 mcg SC weekly.

Q

• Qarziba (dinutuximab beta, EU via EUSA Pharma distribution).

R

• Rituxan (MabThera) — see M.

• Rozlytrek — Entrectinib — NTRK/ROS1 fusion-positive cancers — 600 mg daily.

• Retevmo (selpercatinib, via Loxo/Lilly; co-promote in some regions).

S

• Susvimo — Ranibizumab port delivery system — Wet AMD — Refill q6m.

• Skinovate dermatology legacy line (regional).

• Seqirus vaccine partnerships (non-core).

T

• Tecentriq — Atezolizumab — NSCLC, TNBC, HCC, UC, SCLC, melanoma combos — 1200 mg IV q3w or 1680 mg q4w.

• Tarceva — Erlotinib — EGFR+ NSCLC, pancreatic cancer — 150 mg daily.

• Tenecteplase (TNKase) — Tenecteplase — Acute MI — IV bolus weight-based.

• Tibsovo (ivosidenib — partnered co-rights).

U

• Uridine triacetate (Vistogard distribution in US).

V

• Vabysmo — Faricimab — Wet AMD, DME — 6 mg intravitreal q8–16w after loading.

• Venclexta (AbbVie, co-market US) — Venetoclax — CLL, AML.

• Visudyne — Verteporfin PDT — Wet AMD, CNV — IV 6 mg/m² + laser activation.

• Valcyte — Valganciclovir — CMV infection/prophylaxis — 900 mg BID induction, 900 mg QD maintenance.

• Xolair (co-developed with Novartis) — Omalizumab — Allergic asthma, CSU, nasal polyps — SC q2–4w.

Y

• Yervoy is BMS, not Genentech.

Z

• Zelboraf — Vemurafenib — BRAF V600 melanoma, Erdheim-Chester disease — 960 mg BID.

• Zymessca legacy enzyme therapies (regional).